José Baselga, who has resigned from his positions as physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center, is winding down his research and clinical activities at that institution, officials said.
José Baselga has resigned from his position as physician-in-chief and chief medical officer of Memorial Sloan Kettering Cancer Center less than a week after The New York Times and ProPublica reported that he had failed to disclose his conflicts of interest in scientific and medical journals and at professional meetings.
José Baselga, physician-in-chief and chief medical officer of Memorial Sloan Kettering Cancer Center, has apologized to his executive team for “failing to make appropriate disclosures in scientific and medical journals and at professional meetings.”
Moody Wharam Jr., professor emeritus of radiation oncology and molecular radiation sciences, and former Willard and Lillian Hackerman Professor of Radiation Oncology at the Johns Hopkins Kimmel Cancer Center, died Aug. 10 at age 77.
A working group formed by NCI Director Ned Sharpless has recommended that the institute devote additional funds informatics researchers could use to harmonize existing cancer datasets.
Jim Cox, professor emeritus in radiation oncology at the University of Texas MD Anderson Cancer Center, passed away on Aug. 14. He was 80.
Billy Wayne Ruddick Jr., Ph.D., is a character eerily reminiscent of someone we know, a distant relative who picks political fights on Facebook and Twitter.
With 11 new partners, AACR’s Project GENIE to make available genomic data from 60,000 tumors by 2019
Project GENIE, already the largest publicly available genomic data repository in the U.S., is on track to publish information on 60,000 sequenced tumors—derived from an international network largely comprised of academic cancer centers—by January 2019.
An actuary might note that if you were in residency at the time when the 7+3 protocol of cytarabine and daunorubicin was first used to treat acute myelogenous leukemia, chances are you are considering retirement just about now.
FDA is revamping the gearing in the machinery of approval of cancer drugs, making it possible to initiate regulatory review immediately after the clinical trials datasets are locked.
